Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	-	0.05	0.45
Revenue Growth (YoY)	-	-	-	-89.98%	-
Cost of Revenue	-	-	-	0.01	0.09
Gross Profit	-	-	-	0.03	0.36
Selling, General & Admin	10.61	12.9	15.98	15.9	6.16
Research & Development	9.19	8.88	13.01	7.26	4.67
Total Operating Expenses	19.8	21.78	28.99	23.16	10.84
Operating Income	-19.8	-21.78	-28.99	-23.13	-10.48
Interest Income	0.05	0.18	2.89	-	-
Interest Expense	-0.34	-0.93	-1.07	-0.16	-0.61
Other Non-Operating Income (Expense)	-0.09	0.33	-2.02	-2.13	0.17
Total Non-Operating Income (Expense)	-0.38	-0.42	-0.21	-2.29	-0.44
Pretax Income	-20.13	-22.2	-29.2	-25.42	-10.92
Provision for Income Taxes	0.02	0.01	0.02	0.01	0.01
Net Income	-25.62	-23.81	-29.22	-25.43	-10.93
Minority Interest in Earnings	-0.21	-0.07	-	-	-
Net Income Attributable to Preferred Dividends	5.67	1.67	-	-	-
Net Income to Common	-25.62	-23.81	-29.22	-25.43	-10.93
Shares Outstanding (Basic)	3	1	0	0	0
Shares Outstanding (Diluted)	3	1	0	0	0
Shares Change (YoY)	568.98%	373.05%	99.06%	-56.96%	-
EPS (Basic)	0.34	-35.70	-207.62	-358.80	-66.00
EPS (Diluted)	0.34	-35.70	-207.62	-358.80	-66.00
Free Cash Flow	-21.77	-19.71	-27.57	-13.64	-7.98
Free Cash Flow Per Share	-7.70	-29.55	-195.52	-192.59	-48.49
Gross Margin	-	-	-	68.89%	79.06%
Operating Margin	-	-	-	-51395.56%	-2334.52%
Profit Margin	-	-	-	-56504.44%	-2434.97%
FCF Margin	-	-	-	-30315.56%	-1777.28%
EBITDA	-18.58	-20.24	-27.74	-22.88	-10.33
EBITDA Margin	-	-	-	-50833.33%	-2299.78%
EBIT	-19.8	-21.78	-28.99	-23.13	-10.48
EBIT Margin	-	-	-	-51395.56%	-2334.52%
Effective Tax Rate	-0.10%	-0.06%	-0.05%	-0.04%	-0.10%

Updated Nov 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q